XERS

Xeris Biopharma Holdings, Inc. (XERS) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Xeris Biopharma is a commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases. Its primary commercial products are Recorlev (Cushing's syndrome), Gvoke (severe hypoglycemia), and Keveyis (Primary Periodic Paralysis). The company is also developing XP-8121, a once-weekly subcutaneous levothyroxine.

Key Financial Metrics

Revenue Breakdown (Q3 2025): Recorlev ($37.0M), Gvoke ($25.2M), Keveyis ($11.9M).

Liquidity: The company reported a working capital surplus and believes cash resources are sufficient to sustain operations for at least the next 12 months.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 37.1% quarter-over-quarter and 44.1% year-to-date. Recorlev revenue surged 108.6% in Q3 and 125.5% YTD, driven primarily by increased patient demand and volume.
• Profitability: The company achieved a net income of $0.6 million in Q3 2025, a significant improvement from a net loss of $15.7 million in Q3 2024. Operating income turned positive ($6.7M) compared to a loss of $12.9M in the prior year quarter.
• Cost Management: Cost of goods sold (COGS) as a percentage of product revenue improved to 14.8% in Q3 2025 from 25.7% in Q3 2024, aided by higher sales of lower-cost products and reduced inventory write-offs for Gvoke.
• Debt Reduction: Total debt decreased from $232.1 million to $219.5 million, largely due to the conversion of $15.2 million in 2025 Convertible Senior Notes into common stock during March and April 2025.
• Cash Flow: Operating cash flow improved dramatically to a positive $8.6 million for the nine months ended September 2025, compared to a usage of $39.0 million in the same period in 2024.

Outlook, Risks, and Management Commentary

• Guidance: Management expects to continue incurring net losses for at least the next 12 months despite recent profitability, due to ongoing R&D and commercialization investments.
• Pipeline: The company is working with the FDA to plan and initiate a Phase 3 clinical trial for XP-8121 (once-weekly levothyroxine).
• Debt Maturity: The 2029 Loans (approx. $188M) mature on March 5, 2029, but could mature earlier (January 15, 2028) if the 2028 Convertible Notes are not redeemed or extended. The 2028 Convertible Notes ($33.6M) mature in 2028.
• Risks: Key risks include the ability to raise additional capital on acceptable terms, reliance on single-source suppliers, regulatory approval timelines for pipeline candidates, and macroeconomic factors affecting interest rates and credit markets.
• Unusual Items: The company recognized significant stock-based compensation ($17.1M YTD) and amortization of intangible assets ($8.1M YTD). There were no material legal proceedings as of the filing date.

Investor Verification Checklist

• Debt Covenants: Verify the specific conditions under which the 2029 Loans could mature early in 2028 and the company's plan to refinance or repay the $33.6M 2028 Convertible Notes.
• Recorlev Sustainability: Assess whether the 108% revenue growth in Recorlev is sustainable or driven by temporary factors, given the small market size for Cushing's syndrome.
• Cash Burn vs. Revenue: Monitor the trajectory of operating cash flow to ensure it remains positive as R&D spending for XP-8121 increases.
• Inventory Levels: Review the increase in inventory (from $48.2M to $67.5M) to ensure it aligns with sales growth and does not indicate future write-down risks.
• Dilution: Track the impact of warrant exercises and convertible note conversions on share count, which increased from ~149M to ~165.5M shares outstanding.